Skip to main content
Fig. 5 | Molecular Medicine

Fig. 5

From: Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma

Fig. 5

Mechanisms of vanoxerine dihydrochloride. Vanoxerine dihydrochloride inhibited CDK4/6 phosphorylation and the complex with cyclinD. It also inhibited CDK2 phosphorylation and the complex with cyclinE. Together, they suppress the hyperphosphorylation of RB, and the releases of pRB from its association with transcription factor E2F. As a result, it inhibits the cell cycle to proceed from G1 to S-phase. In addition, vanoxerine dihydrochloride also reduced cyclinA-CDK2 complex, and inhibited DNA replication and decrease S and G2-M phases

Back to article page

Molecular Medicine

ISSN: 1528-3658